pelvic organ prolapse
Conditions
Interventions
experimental group:Nilestriol Tablets
Sponsors
Second Xiangya Hospital of CSU
Eligibility
Sex/Gender
Female
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria of prospective test group: 30 women aged 40-80 years old with postmenopausal pelvic organ prolapse to be treated surgically, who were examined according to the POP-Q quantitative evaluation system as having uterine prolapse of II-IV degree with different degrees of vaginal anterior and posterior wall prolapse. The following conditions were also met: (1) menopause for more than 1 year; (2) vaginal ultrasound: endometrial thickness 40U/L and estradiol (E2) < 30 pg /mL; (4) no cervical lesions; (5) combined with senile vaginitis. 2. Inclusion criteria for retrospective control group: a total of 30 pelvic organ prolapse surgery patients who had a complete record of the course of the disease and were treated regularly with local oestrogens before and after surgery according to the doctor's instructions.
Exclusion criteria
Exclusion criteria: 1. Prospective experimental group exclusion criteria: (1) allergy to any component of nilestrol; (2) patients with possible or suffering from breast cancer, estrogen-dependent tumours; (3) patients with unexplained vaginal bleeding; (4) patients with severe hepatic and renal dysfunction; (5) patients with active thromboembolic disease; (6) patients with hormone replacement therapy prior to drug administration; (7) patients with uncontrolled severe hypertension and diabetes mellitus. Patients. 2. Exclusion criteria of retrospective control group: (1) patients who are allergic to any components of topical estrogen; (2) patients with possible or suffering from breast cancer or estrogen-dependent tumours; (3) patients with unexplained vaginal bleeding; (4) patients with liver insufficiency or diseases that lead to abnormal results of liver function tests; (5) patients with active thromboembolic diseases; (6) patients who have used hormone replacement therapy prior to the administration of the drug. (7) Patients with uncontrolled severe hypertension and diabetes mellitus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| peroperative bleeding;time of operation;Postoperative hospital stay; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal health condition;Satisfaction score of the surgeon during the operation;E2;endometrial thickness;FSH; | — |
Countries
China
Contacts
Public ContactXiaomeng Xia
Second Xiangya Hospital of CSU
Outcome results
None listed